MetaCap

NanoViricides (NNVC) vs ProMIS Neurosciences (PMN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NanoViricides (NNVC) has outperformed ProMIS Neurosciences (PMN) over the past year, losing 10.2% versus a loss of 69.9%. Over five years, NNVC leads with a -76.5% price change compared with -98.2% for PMN. NanoViricides is the larger company by market cap ($29.1 million vs $28.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NNVC-10.24%PMN-69.90%
+146%+32%-82%
Nov 21, 20251 yearNov 20, 2026
NNVC-75.16%PMN-98.38%
+24%-40%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NNVC versus PMN key metrics
MetricNNVCPMN
Share price$1.14$3.16
Market cap$29.13M$28.43M
1-day change-2.56%-1.56%
YTD return+0.88%-53.73%
1-year return-10.24%-69.90%
5-year return-76.54%-98.24%
EPS (TTM)$-0.53$-6.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-8.22M$-39.72M
52-week high$1.93$27.40
52-week low$0.85$2.78
Distance from 52-week high-40.93%-88.47%
Analyst consensusstrong_buynone
Avg. price target upside+426.32%+1248.42%
Average volume356.86K164.88K
Shares outstanding25.55M9.00M
Employees710
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NNVC has outperformed PMN by 59.7 percentage points over the past year.

About NanoViricides

NNVC stock →

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About ProMIS Neurosciences

PMN stock →

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

NNVC vs PMN FAQ

Which is bigger, NanoViricides or ProMIS Neurosciences?

NanoViricides (NNVC) is larger, with a market capitalization of $29.13M compared with $28.43M for ProMIS Neurosciences (PMN).

Which stock has performed better over the past year, NNVC or PMN?

NNVC returned -10.24% over the past 12 months, compared with -69.90% for PMN (price return, excluding dividends). Past performance does not predict future results.

Are NanoViricides and ProMIS Neurosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons